News & Events

Weekly Media Tip Sheet

FDA News & Notes – Week of Feb. 20, 2017

Science, public health, and regulatory highlights from the U.S. Food and Drug Administration. Information in this document is designed for credentialed journalists. Release dates and times for items are current as of Feb.20, 2017. Times listed are local time.

FDA News & Notes does not contain any regulatory or enforcement actions due to legal limitations.

Meetings, Workshops and Congressional Testimony:
     
Thursday, 2/23 – The Circulatory System Devices Panel of the Medical Devices Advisory Committee will meet to discuss the safety and efficacy of device application for Claret Medical, Inc. - Sentinel Cerebral Protection System. The meeting will be held from 8 a.m. – 6 p.m. at the Hilton at 620 Perry Parkway, Gaithersburg, Maryland.
Press Office Contact: Stephanie Caccomo, 301-348-1956, stephanie.caccomo@fda.hhs.gov 
 
Did You Know?
     
Speakers from the FDA’s Office of Prescription Drug Promotion will present at the DIA annual Advertising and Promotion Regulatory Affairs Conference about two recent draft guidances related to medical product communications. The conference will be held on February 23-24, 2017 from 7 a.m. to 5 p.m. at the Omni Shoreham Hotel in Washington, D.C. More information can be found heredisclaimer icon.
 
In Case You Missed It:
     
Thursday, 2/16 – Consumer Health Information: Controlling Cholesterol with Statins.  You go to the gym faithfully, and try to watch your diet. But after your annual physical, you find out that your blood cholesterol is surprisingly high. Your doctor calls you back to discuss taking a medication known as a statin.
Press Office Contact: FDA Office of Media Affairs, 301-796-4540, fdaoma@fda.hhs.gov
 
Wednesday, 2/15 – News Release: FDA approves new psoriasis drug. The FDA approved Siliq (brodalumab) to treat adults with moderate-to-severe plaque psoriasis. Siliq is administered as an injection.
Press Office Contact: Andrea Fischer, 301-796-0393, andrea.fischer@fda.hhs.gov 
 
Tuesday, 2/14 – Consumer Health Information: FDA-Approved Devices That Keep the Heart Beating. Heart disease, also called “cardiovascular disease,” can have serious consequences. In fact, heart disease is the leading cause of death for men and women in the United States, according to the Centers for Disease Control and Prevention. But medical devices, such as pacemakers and defibrillators, have extended and improved the lives of millions of people worldwide.
Press Office Contact: FDA Office of Media Affairs, 301-796-4540, fdaoma@fda.hhs.gov
 
Tuesday, 2/14 – Consumer Health Information: How Devices in Public Places Can Restart Hearts. Sudden cardiac arrest occurs when the heart suddenly and unexpectedly stops pumping blood. It can happen to anyone, at any time, and signs include sudden collapse and immediate loss of consciousness.
Press Office Contact: FDA Office of Media Affairs, 301-796-4540, fdaoma@fda.hhs.gov
 
Monday, 2/13 – FDA Voice Blog: FDA Drug Trials Snapshots and Diversity When Testing New Drugs. Did you know that some drugs affect men and women differently? For instance, women are often prescribed only half the dose that men take of the sleep medication, Ambien (zolpidem). Race and ethnicity also make a difference. One type of drug commonly used to treat high blood pressure, angiotensin-converting enzyme inhibitors, has been shown to be less effective in African American patients than in white patients.
Press Office Contact: FDA Office of Media Affairs, 301-796-4540, fdaoma@fda.hhs.gov
 
 

FDA Office of Media Affairs Contact Information:

Media Inquiries: FDA Office of Media Affairs, 301-796-4540, fdaoma@fda.hhs.gov
List of FDA Press Officers and beats

More Resources:

Read our Blog: FDA Voice
FDA Photosdisclaimer icon (Flickr)
Consumer Health Information
Scientific Publications by FDA Staff

 

Page Last Updated: 02/21/2017
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English